Heart Failure, Systolic
Conditions
Brief summary
The study measure multiple neurohormones in patients with heart failure being treated with Sacubitril/Valsartan in increasing doses over an 8 week period.
Interventions
Increasing doses of Sacubitril/Valsartan
Sponsors
Oslo University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Patients must give written informed consent before any study assessment is performed. 2. Ambulatory ≥ 18 years of age, male or female, treated at Ringerike Hospital. 3. Patients with symptomatic chronic heart failure and reduced ejection fraction (≤ 40%). 4. Patients on optimized medical treatment for heart failure. -
Exclusion criteria
1. Patients not able to comply in the study. 2. Patients having contraindication for treatment with Entresto; 1. Hypersensitivity to the active substances or to any of the excipients listed in section 2. Hyperkalemia: \> 5.4 mmol/L 3. Known history of angioedema related to previous ACE inhibitor or ARB therapy. 4. Hereditary or idiopathic angioedema. 5. Concomitant use with Aliskiren-containing medicinal products in patients with diabetes mellitus or in patients with renal impairment (eGFR \<60 ml/min/1.73m2) 6. End-stage renal disease (\<15 mL/min per 1.73m2 or treatment by dialysis). 7. Severe hepatic impairment, biliary cirrhosis and cholestasis (Child-Pugh C classification). 8. Pregnancy Breast-feeding-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neurohormonal plasma concentration | 8 weeks |
Countries
Norway
Contacts
Primary ContactChristian Hall, MD PhD
Backup ContactIngeborg Haugli, MD
Outcome results
None listed